Skip to content

Effects of Remazolam Toluenesulfonate on Hemodynamics, Lung Function, Recovery, Postoperative Complications and Postoperative Cognitive Function in Patients with Radical Lung Cancer

Effects of Remazolam Toluenesulfonate on Hemodynamics, Lung Function, Recovery, Postoperative Complications and Postoperative Cognitive Function in Patients with Radical Lung Cancer

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100050236
Enrollment
Unknown
Registered
2021-08-24
Start date
2021-08-24
Completion date
Unknown
Last updated
2022-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Radical resection of pulmonary carcinoma

Interventions

experimental group:Remazolam Toluenesulfonate
control group:Propofol

Sponsors

The First Affiliated Hospital of Nanchang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Male or female subjects, aged from 18 to 65 years, more than 5 years of education; 2. For patients undergoing thoracoscopic lobectomy and undergoing one-lung ventilation during operation, the operation time is expected to exceed 1.5 hours; 3. ASA grade I-II, and deep vein and radial artery puncture should be done during operation; 4.The score of mini-mental examination (MMSE) before operation was >=21 points.

Exclusion criteria

Exclusion criteria: 1. Allergic to benzodiazepines and allergic to other narcotic drugs; 2. Severe pulmonary ventilation, pulmonary ventilation dysfunction, poor lung function before operation, inability to tolerate one-lung ventilation, severe COPD, pulmonary encephalopathy and severe cor pulmonale before operation; 3. Systolic blood pressure < 90mmHg in quiet state or poor control of hypertension with antihypertensive drugs, sinus bradycardia or atrioventricular block before operation, severe arrhythmia, angina pectoris, diabetes, anemia, acute lung infection, liver and kidney insufficiency; 4. Patients who have taken other clinical trial drugs in the last 4 months; 5. Lactating women during pregnancy; 6. Severe arrhythmia and angina pectoris, smoking and quitting time less than 2 weeks, long-term alcoholism, drug abuse, taking sedatives, taking antidepressants; 7. Severe cerebrovascular diseases are suffering from central nervous system diseases, psychosis, psychological diseases, long-term drug treatment and recent neurosurgery.

Design outcomes

Primary

MeasureTime frame
Blood gas analysis;Hemodynamics;Pulmonary function;Min-i mental state examination;BIS;IL-8;IL-6;SOD;MDA;

Countries

China

Contacts

Public ContactWei Fusheng

The First Affiliated Hospital of Nanchang University

1047450471@qq.com+86 13755645791

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026